Arnuity Ellipta (Fluticasone Furoate) Patent Expiration, LOE Window & CMS Spending

Arnuity Ellipta (Fluticasone Furoate) by GSK: FDA Orange Book LOE 2026-03-01, 12 AB generics, $231.0M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGSK
FDA Application & PathwayN205625 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2026-03-01
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors12
2024 CMS Total Public Spend$231.0M
2024 Medicare Part D Spend$199.9M
2024 Medicaid Spend$31.2M
Reported Wholesale Price Change (CA SB 17)5 WAC filings (max 16.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.